SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (Nasdaq – TALS)

BALA CYNWYD – July 27 2023 /NewFile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Talaris Therapeutics, Inc. (“Talaris”) (“Talaris” or the “Company”) (Nasdaq – TALS) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Tourmaline Bio, Inc. (“Tourmaline”). Under the terms of the Agreement, Tourmaline stockholders will receive shares of Talaris common stock. In addition to their shares of Talaris common stock, Talaris stockholders will participate in a cash dividend of up to approximately $64.8 million in connection with, and prior to, the Merger. Tourmaline stockholders immediately prior to the Merger are expected to own approximately 78.7% of the combined company and Talaris stockholders immediately prior to the Merger are expected to own approximately 21.3% of the combined company, each on a fully diluted basis.

The investigation concerns whether the Talaris Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Talaris shareholders in the combined company.

If you own shares of Talaris stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.